Wegovy Results: What the Evidence Really Shows

The biggest misconception: that the trial average is your personal target

A lot of people come to Wegovy having read the headline figure (15% weight loss) and treat it as a floor rather than an average. It isn't. In the STEP 1 trial, published in the New England Journal of Medicine, that 15% average was drawn from a large group of adults with a wide range of starting weights, health backgrounds and responses to treatment. Some participants lost closer to 20%; others lost 6% or 7%. Both outcomes were real, and both were meaningful.

It is worth letting go of the idea that the average is a promise. What the trials show is that semaglutide consistently outperforms placebo by a substantial margin, but the degree of effect depends on how your body responds, how well the dose is tolerated, and what changes you make alongside treatment. Our prescribers are asked this question most weeks, and the honest answer is always the same: there is no way to know your result in advance, only to start carefully and see.

Wegovy works by activating GLP-1 receptors in the brain and gut, reducing appetite signals and slowing how quickly the stomach empties. If you are weighing up whether Wegovy really works before committing, you can also read more about the mechanism on the Wegovy overview page. The biology is sound; the variation is human.

What the newer 7.2 mg dose adds to the results picture

Until recently, 2.4 mg was the ceiling for Wegovy. In January 2026 the MHRA approved a 7.2 mg maintenance dose, and on 14 April 2026 a dedicated single-dose 7.2 mg pen received approval, confirmed by the MHRA's announcement on GOV.UK. Trials at this higher dose reported around 20.7% average weight loss over 72 weeks, which starts to approach what has been seen with tirzepatide (Mounjaro) at its highest doses.

The 7.2 mg pen is licensed for adults with a BMI of 30 or above; it is not for people with a BMI below 30 or for the cardiovascular indication. Starting dose remains 0.25 mg (titrated upward by the prescriber, typically with a minimum of four weeks at each level) before reaching 7.2 mg as the maximum. The titration schedule matters: moving too quickly tends to worsen gastrointestinal side effects without improving results.

If you want to understand whether Wegovy genuinely delivers on its weight loss promise beyond the headlines, the detailed effectiveness page pulls together the evidence clearly. Whether 2.4 mg or 7.2 mg is relevant for you is a clinical question, not a reading exercise.

Side effects and how they affect what results look like in practice

Results and tolerability are connected. The most common side effects of Wegovy are gastrointestinal: nausea, loose stools, constipation, indigestion and, for some people, vomiting. These are most noticeable after starting treatment or after a dose increase, and for many they ease within a couple of weeks. For others they persist longer, and the prescriber may slow the titration or hold a dose.

That matters for results because the temptation to rush through doses is real, a higher dose produced better average weight loss in the trials, so people naturally want to get there. But tolerating a lower dose for longer often leads to better outcomes than pushing through side effects that are disruptive enough to affect eating, hydration or the willingness to continue treatment at all.

The semaglutide information page covers the full side-effect profile in plain language. For a comparison of how Wegovy's tolerability profile sits alongside other options, the weight-loss treatments overview gives a grounded starting point. The NHS also maintains a straightforward patient-level guide at nhs.uk/medicines/semaglutide.

Who the results apply to, and the role of clinical assessment

The STEP 1 trial enrolled adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition, without type 2 diabetes. That broadly mirrors Wegovy's UK licence. Results in people with type 2 diabetes, studied separately, tended to be somewhat lower on average, which is consistent with how GLP-1 medicines behave across conditions.

Ethnic-background BMI thresholds are 2.5 kg/m² lower under UK guidance, so the eligibility criteria reach a broader group than the headline numbers suggest. BMI alone, though, does not decide suitability. A prescriber reviews your full medical picture (other medications, relevant health history, current conditions) before treatment is considered appropriate.

Private treatment costs are worth understanding honestly before you start; the Wegovy price comparison page sets out the UK private market context clearly. At nume, every consultation is reviewed by a GPhC-registered Independent Prescriber, a real clinician reads your answers, not software. If you want to explore whether Wegovy is right for you, speak to our prescribers through a free consultation.